Jennifer E Ho1, Emily K Zern2, Emily S Lau2, Luke Wooster2, Cole S Bailey2, Thomas Cunningham2, Aaron S Eisman2, Kathryn M Hardin2, Robyn Farrell2, John A Sbarbaro2, Mark W Schoenike2, Nicholas E Houstis2, Aaron L Baggish2, Ravi V Shah2, Matthew Nayor2, Rajeev Malhotra3, Gregory D Lewis4. 1. Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts; Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: jho1@mgh.harvard.edu. 2. Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 3. Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts; Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 4. Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: glewis@partners.org.
Abstract
BACKGROUND: Abnormal pulmonary arterial pressure (PAP) responses to exercise have been described in select individuals; however, clinical and prognostic implications of exercise pulmonary hypertension (exPH) among broader samples remains unclear. OBJECTIVES: This study sought to investigate the association of exPH with clinical determinants and outcomes. METHODS: The authors studied individuals with chronic exertional dyspnea and preserved ejection fraction who underwent cardiopulmonary exercise testing with invasive hemodynamic monitoring. Exercise pulmonary hypertension was ascertained using minute-by-minute PAP and cardiac output (CO) measurements to calculate a PAP/CO slope, and exPH defined as a PAP/CO slope >3 mm Hg/l/min. The primary outcome was cardiovascular (CV) hospitalization or all-cause mortality. RESULTS: Among 714 individuals (age 57 years, 59% women), 296 (41%) had abnormal PAP/CO slopes. Over a mean follow-up of 3.7 ± 2.9 years, there were 208 CV or death events. Individuals with abnormal PAP/CO slope had a 2-fold increased hazard of future CV or death event (multivariable-adjusted hazard ratio: 2.03; 95% confidence interval: 1.48 to 2.78; p < 0.001). The association of abnormal PAP/CO slope with outcomes remained significant after excluding rest PH (n = 146, hazard ratio: 1.75; 95% confidence interval: 1.21 to 2.54; p = 0.003). Both pre- and post-capillary contributions to exPH independently predicted adverse events (p < 0.001 for both). CONCLUSIONS: Exercise pulmonary hypertension is independently associated with CV event-free survival among individuals undergoing evaluation of chronic dyspnea. These findings suggest incremental value of exercise hemodynamic assessment to resting measurements alone in characterizing the burden of PH in individuals with dyspnea. Whether PH and PH subtypes unmasked by exercise can be used to guide targeted therapeutic interventions requires further investigation.
BACKGROUND: Abnormal pulmonary arterial pressure (PAP) responses to exercise have been described in select individuals; however, clinical and prognostic implications of exercise pulmonary hypertension (exPH) among broader samples remains unclear. OBJECTIVES: This study sought to investigate the association of exPH with clinical determinants and outcomes. METHODS: The authors studied individuals with chronic exertional dyspnea and preserved ejection fraction who underwent cardiopulmonary exercise testing with invasive hemodynamic monitoring. Exercise pulmonary hypertension was ascertained using minute-by-minute PAP and cardiac output (CO) measurements to calculate a PAP/CO slope, and exPH defined as a PAP/CO slope >3 mm Hg/l/min. The primary outcome was cardiovascular (CV) hospitalization or all-cause mortality. RESULTS: Among 714 individuals (age 57 years, 59% women), 296 (41%) had abnormal PAP/CO slopes. Over a mean follow-up of 3.7 ± 2.9 years, there were 208 CV or death events. Individuals with abnormal PAP/CO slope had a 2-fold increased hazard of future CV or death event (multivariable-adjusted hazard ratio: 2.03; 95% confidence interval: 1.48 to 2.78; p < 0.001). The association of abnormal PAP/CO slope with outcomes remained significant after excluding rest PH (n = 146, hazard ratio: 1.75; 95% confidence interval: 1.21 to 2.54; p = 0.003). Both pre- and post-capillary contributions to exPH independently predicted adverse events (p < 0.001 for both). CONCLUSIONS: Exercise pulmonary hypertension is independently associated with CV event-free survival among individuals undergoing evaluation of chronic dyspnea. These findings suggest incremental value of exercise hemodynamic assessment to resting measurements alone in characterizing the burden of PH in individuals with dyspnea. Whether PH and PH subtypes unmasked by exercise can be used to guide targeted therapeutic interventions requires further investigation.
Authors: R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger Journal: Eur Respir J Date: 2005-11 Impact factor: 16.671
Authors: Gabor Kovacs; Alexander Avian; Michael Pienn; Robert Naeije; Horst Olschewski Journal: Am J Respir Crit Care Med Date: 2014-08-01 Impact factor: 21.405
Authors: Bradley A Maron; Edward Hess; Thomas M Maddox; Alexander R Opotowsky; Ryan J Tedford; Tim Lahm; Karen E Joynt; Daniel J Kass; Thomas Stephens; Maggie A Stanislawski; Erik R Swenson; Ronald H Goldstein; Jane A Leopold; Roham T Zamanian; Jean M Elwing; Mary E Plomondon; Gary K Grunwald; Anna E Barón; John S Rumsfeld; Gaurav Choudhary Journal: Circulation Date: 2016-02-12 Impact factor: 29.690
Authors: Philipp Douschan; Gabor Kovacs; Alexander Avian; Vasile Foris; Fabian Gruber; Andrea Olschewski; Horst Olschewski Journal: Am J Respir Crit Care Med Date: 2018-02-15 Impact factor: 21.405
Authors: James J Tolle; Aaron B Waxman; Teresa L Van Horn; Paul P Pappagianopoulos; David M Systrom Journal: Circulation Date: 2008-11-03 Impact factor: 29.690
Authors: Barry A Borlaug; John Blair; Martin W Bergmann; Heiko Bugger; Dan Burkhoff; Leonhard Bruch; David S Celermajer; Brian Claggett; John G F Cleland; Donald E Cutlip; Ira Dauber; Jean-Christophe Eicher; Qi Gao; Thomas M Gorter; Finn Gustafsson; Chris Hayward; Jan van der Heyden; Gerd Hasenfuß; Scott L Hummel; David M Kaye; Jan Komtebedde; Joseph M Massaro; Jeremy A Mazurek; Scott McKenzie; Shamir R Mehta; Mark C Petrie; Marco C Post; Ajith Nair; Andreas Rieth; Frank E Silvestry; Scott D Solomon; Jean-Noël Trochu; Dirk J Van Veldhuisen; Ralf Westenfeld; Martin B Leon; Sanjiv J Shah Journal: Circulation Date: 2022-03-31 Impact factor: 39.918
Authors: Matthew Nayor; Nicholas E Houstis; Mayooran Namasivayam; Jennifer Rouvina; Charles Hardin; Ravi V Shah; Jennifer E Ho; Rajeev Malhotra; Gregory D Lewis Journal: JACC Heart Fail Date: 2020-06-10 Impact factor: 12.035
Authors: Bradley A Maron; Gabor Kovacs; Anjali Vaidya; Deepak L Bhatt; Rick A Nishimura; Susanna Mak; Marco Guazzi; Ryan J Tedford Journal: J Am Coll Cardiol Date: 2020-12-01 Impact factor: 24.094
Authors: Bradley A Maron; Steven H Abman; C Greg Elliott; Robert P Frantz; Rachel K Hopper; Evelyn M Horn; Mark R Nicolls; Oksana A Shlobin; Sanjiv J Shah; Gabor Kovacs; Horst Olschewski; Erika B Rosenzweig Journal: Am J Respir Crit Care Med Date: 2021-06-15 Impact factor: 30.528